Unmet Needs in the Management of Advanced Renal Cell Carcinoma

Video

Shared insight from Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, on unmet needs in the setting of clear cell and non–clear cell renal cell carcinoma.

Transcript:

Moshe Ornstein, MD: We’ve spent a good amount of time talking about these combinations. We should mention that we’re talking specifically about data in the clear cell RCC [renal cell carcinoma] setting. What do you see in terms of updates and unmet needs in patients with advanced non–clear cell carcinoma?

Ulka N. Vaishampayan, MBBS: Non–clear cell has been tougher to do trials in. Typically we’ve translated the same agents used in clear cell into the non–clear cell arena. Because they were FDA approved for kidney cancer in general, we’ve been able to gain access to them. The SWOG 1500 study, reported earlier this year, compared sunitinib with cabozantinib. It was originally a 4-arm study, but the pure MET inhibitors didn’t show adequate response to move forward. It ended up being a study that compared cabozantinib with sunitinib, and cabozantinib showed improved PFS [progression-free survival]. That’s the new standard in metastatic papillary kidney cancer. All the others—the chromophobe, medullary carcinomas, etc—remained untouched in terms of therapeutic agents. We need dedicated studies, and finding targets in those malignancies might be a start toward developing treatments for it.

The other unmet need is the subgroups of kidney cancer that aren’t doing as well as expected. For instance, patients who present with synchronous primary tumor and metastases have half the median survival: 26 months, compared with 48 months with ipilimumab-nivolumab, for instance. Even with contemporary immune checkpoint therapy, those patients aren’t doing as well as patients who’ve had nephrectomy and then relapsed a few years later with metastases. In that patient population, there are nephrectomy trials that have been conducted in the past. About 2 decades ago, the SWOG study showed benefit for upfront nephrectomy. Now the pendulum has swung to say systemic therapy is the mainstay of treatment, and cytoreductive nephrectomy may not add anything that was reported in the CARMENA trial. Our current SWOG trial, 1931, or the PROBE trial, is trying to compare a systemic immune-based checkpoint regimen combination therapy plus minus cytoreductive nephrectomy. Support that study and help us answer this question.

Moshe Ornstein, MD: It’s important to understand that the pendulum has swung. We don’t know what to do for these patients, so we take it 1 patient at a time.

Ulka N. Vaishampayan, MBBS: Absolutely.

Moshe Ornstein, MD: It’s great to have these studies, especially the PROBE study that you’re leading, that can help answer this question in terms of the timing of cytoreductive nephrectomy for patients who present with a localized mass but also with extensive metastatic disease.

Transcript edited for clarity.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Related Content
Addressing Gaps in Education for Non–Clear Cell RCC

Addressing Gaps in Education for Non–Clear Cell RCC

ONCOLOGY Staff
November 19th 2024
Article

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.

Benmelstobart Combo Improves Outcomes Vs Sunitinib in Advanced RCC

Kyle Doherty
September 19th 2024
Article

Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC

Alexander Spira, MD, PhD, FACP;Millie Das, MD;Joshua K. Sabari, MD;Misako Nagasaka, MD
September 4th 2023
Podcast

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Belzutifan Significantly Improves PFS Vs Everolimus in Clear Cell RCC

Russ Conroy
September 4th 2024
Article

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.

Exercise Oncology May Improve HRQOL in Metastatic RCC

Ariana Pelosci
July 30th 2024
Article

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.